Cytokine Signalling Forum

Publications





December 16

Efficacy of VX-509 (decernotinib) in Combination with a Disease-modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis: Clinical and MRI Findings

Genovese M, Yang F, Østergaard M and Kinnman N.
Ann Rheum Dis 2016;75:1979–83

This Phase 2b study of VX-509 (decernotinib), a selective JAK3 inhibitor, showed that VX-509 in combination with stable DMARD therapy was effective for improving synovitis and osteitis as assessed by MRI in patients who had an inadequate response to DMARD therapy. Patients were randomised to treatment groups receiving either placebo, VX-509 100 mg, 200 mg or 300 mg for 12 weeks. Minimum inclusion criteria included Grade ≥2 clinical synovitis in either the wrist or two metacarpophalangeal joi...

Keywords: JAK, Decernotinib, Clinical, Phase 2